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Background: The marked neurohormonal activation that occurs in chronic systolic heart failure perpetuates the deterioration of left 
ventricular ejection fraction (LVEF) and progressive left ventricular dilatation. This process of ventricular remodeling has been shown to be 
favorably altered by angiotensin-converting enzyme inhibitors, beta-blockers and aldosterone antagonists. However, there is individual and 
racial variation in response to therapy. We sought to identify racial differences on reverse left ventricular remodeling in patients with chronic 
systolic heart failure while on guideline-directed medical therapy (GDMT).
methods: We retrospectively reviewed the medical records of 126 consecutive patients diagnosed with heart failure with reduced ejection 
fraction (LVEF ≤ 40%). Baseline demographic, clinical and echocardiographic variables were collected prior to initiation of GDMT. We then 
measured the change in left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and severity of mitral 
regurgitation (MR) at 12 and 24 months after starting GDMT. The primary end point was reverse LV remodeling, which was defined as a 
composite of improvement in LVEF, LVEDD or severity of MR.
results: On Cox proportional hazard model non-AAs were twice as likely as AAs to have improvement in the primary endpoint at 12 
months (HR 1.97, 95% CI: 1.21 to 3.84, p = 0.04) and 24 months (HR 1.72, 95% CI: 1.21 to 2.94, p = 0.04) after initiation of GDMT. AAs 
had significant improvement in LVEF after 12 months (p = 0.03) but not in LVEDD (p = 0.66) or severity of MR (p = 0.49) compared to 
baseline. In addition, presence of diabetes mellitus (HR = 0.45, 95% CI: 0.226 to 0.925 p=0.02) was an independent negative predictor of 
reverse LV remodeling.
conclusion:  Our study shows that there are racial disparities in improvement of LV remodeling with non-AAs appearing to have a greater 
benefit than AAs. These findings have to be evaluated further in large scale randomized trials.
